--- title: "Canopy Growth | 8-K: FY2027 Q1 Revenue Beats Estimate at CAD 81.17 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295224707.md" datetime: "2026-08-07T11:08:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295224707.md) - [en](https://longbridge.com/en/news/295224707.md) - [zh-HK](https://longbridge.com/zh-HK/news/295224707.md) generator: "portal-rs" --- # Canopy Growth | 8-K: FY2027 Q1 Revenue Beats Estimate at CAD 81.17 M Revenue: As of FY2027 Q1, the actual value is CAD 81.17 M, beating the estimate of CAD 58.78 M. EPS: As of FY2027 Q1, the actual value is CAD -0.03. EBIT: As of FY2027 Q1, the actual value is CAD -14.71 M. #### Consolidated Financial Performance Canopy Growth Corporation reported consolidated net revenue of $81.2 million in Q1 FY2027, an increase of 13% compared to $72.1 million in Q1 FY2026. The consolidated gross margin was 27% in Q1 FY2027, up from 25% in Q1 FY2026, and the adjusted gross margin improved to 31% from 25% in the prior year period. Selling, general and administrative expenses increased by 6% to $40.2 million in Q1 FY2027 from $38.1 million in Q1 FY2026. The company’s net loss significantly narrowed by 68% to - $14.6 million in Q1 FY2027, compared to - $44.9 million in Q1 FY2026. Adjusted EBITDA loss improved by 59% year-over-year, narrowing to - $3.2 million in Q1 FY2027 from - $7.9 million in Q1 FY2026. Free cash outflow increased to - $25.7 million in Q1 FY2027 from - $11.6 million in Q1 FY2026. Cash used in operating activities was - $25.0 million in Q1 FY2027 compared to - $10.3 million in Q1 FY2026. Purchases of property, plant, and equipment were - $0.7 million in Q1 FY2027, down from - $1.3 million in Q1 FY2026. Cash and cash equivalents stood at $336.6 million as of June 30, 2026, a decrease from $364.7 million at March 31, 2026. #### Segment Revenue - **Cannabis Segment**: Net revenue for the Cannabis segment was $65.1 million in Q1 FY2027, an increase of 14% compared to $57.0 million in the prior-year period. The segment’s gross margin was 22% in Q1 FY2027, down from 24% in Q1 FY2026, while its adjusted gross margin increased to 26% from 24%. - **Canada Medical Cannabis**: Net revenue grew by 22% to $25.8 million in Q1 FY2027 from $21.2 million in Q1 FY2026, driven by an increase in insured customers and the acquisition of MTL Cannabis, partially offset by a reduction in the Veterans Affairs Canada reimbursement rate. - **Canada Adult-Use Cannabis**: Net revenue increased by 10% to $29.7 million in Q1 FY2027 from $27.0 million in Q1 FY2026, primarily due to higher flower sales following the MTL Cannabis acquisition, partially offset by declines in opportunistic bulk sales. - **International Markets Cannabis**: Net revenue increased by 10% to $9.6 million in Q1 FY2027 from $8.8 million in Q1 FY2026, mainly attributed to strong performance in Europe, particularly Poland. - **Storz & Bickel Segment**: Net revenue was $16.1 million in Q1 FY2027, a 6% increase compared to $15.2 million in Q1 FY2026. The segment’s gross margin significantly improved to 48% in Q1 FY2027 from 29% in Q1 FY2026, due to cost rationalization and recovery of certain U.S. tariffs. #### Operational Highlights Canopy Growth Corporation’s Apollo Cannabis Clinics were recognized as the Best Medical Cannabis Clinic in the 2025 Toronto Star Readers’ Choice Awards. The company improved its adult-use market ranking to #6 overall in Canada, holding top 2 positions in premium flower, infused pre-rolls, and oils & softgels. Spectrum Therapeutics introduced new 30 and 90-pack formats for its softgels, and the Tweed brand was relaunched in the German medical cannabis market utilizing MTL Cannabis’ premium genetics. #### Outlook Canopy Growth Corporation expects to achieve further growth by elevating cultivation and increasing the supply of high-quality flower to meet growing demand in Canada and internationally. The company anticipates further improvements in its financial results, particularly in the second half of fiscal 2027, as the integration of MTL Cannabis is completed. This progress is expected to be driven by top-line growth combined with disciplined cost management, leading to steady improvements in gross margin and adjusted EBITDA. ### Related Stocks - [CGC.US](https://longbridge.com/en/quote/CGC.US.md) ## Related News & Research - [Canopy Growth publishes FY2026 annual report](https://longbridge.com/en/news/296603480.md) - [Canopy Growth publishes fiscal 2026 annual report to shareholders](https://longbridge.com/en/news/296098371.md) - [BioSyent GAAP EPS of C$0.25, revenue of C$19.87M](https://longbridge.com/en/news/296538491.md) - [Insider Selling: Alvopetro Energy (CVE:ALV) Director Sells 10,200 Shares](https://longbridge.com/en/news/296081468.md) - [Evolve Future Leadership Fund - ETF Hedged declares CAD 0.21 dividend](https://longbridge.com/en/news/296299467.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**